ADC Therapeutics SA Publishes Corporate Presentation Highlighting ZYNLONTA® Expansion and Advancements in ADC Pipeline

Reuters

2025/10/13

<a href="https://laohu8.com/S/ADCT">ADC Therapeutics SA</a> Publishes Corporate Presentation Highlighting ZYNLONTA® Expansion and Advancements in ADC Pipeline

ADC Therapeutics SA has released a new corporate presentation highlighting its commercial-stage activities in the field of antibody-drug conjugates (ADCs). The company is focused on expanding its FDA-approved therapy ZYNLONTA® for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), with ongoing research into its use in earlier lines of therapy and additional indications, including combination regimens and treatment of indolent lymphomas. The presentation also outlines progress on a next-generation, PSMA-targeting ADC candidate that is advancing towards investigational new drug (IND) enabling activities. Internal market research is referenced to show ZYNLONTA's current position within U.S. treatment options for r/r DLBCL and potential for market share growth through combination therapies. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2575058844"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575058844\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575058844?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 19:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575058844","market":"us","top_or_hot":-1,"title":"ADC Therapeutics SA Publishes Corporate Presentation Highlighting ZYNLONTA® Expansion and Advancements in ADC Pipeline","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ADCT\">ADC Therapeutics SA</a> Publishes Corporate Presentation Highlighting ZYNLONTA® Expansion and Advancements in ADC Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ADC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> SA has released a new corporate presentation highlighting its commercial-stage activities in the field of antibody-drug conjugates (ADCs). The company is focused on expanding its FDA-approved therapy ZYNLONTA® for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), with ongoing research into its use in earlier lines of therapy and additional indications, including combination regimens and treatment of indolent lymphomas. The presentation also outlines progress on a next-generation, PSMA-targeting ADC candidate that is advancing towards investigational new drug (IND) enabling activities. Internal market research is referenced to show ZYNLONTA's current position within U.S. treatment options for r/r DLBCL and potential for market share growth through combination therapies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADC Therapeutics SA Publishes Corporate Presentation Highlighting ZYNLONTA® Expansion and Advancements in ADC Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADC Therapeutics SA Publishes Corporate Presentation Highlighting ZYNLONTA® Expansion and Advancements in ADC Pipeline\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-13 19:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ADCT\">ADC Therapeutics SA</a> Publishes Corporate Presentation Highlighting ZYNLONTA® Expansion and Advancements in ADC Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ADC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> SA has released a new corporate presentation highlighting its commercial-stage activities in the field of antibody-drug conjugates (ADCs). The company is focused on expanding its FDA-approved therapy ZYNLONTA® for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), with ongoing research into its use in earlier lines of therapy and additional indications, including combination regimens and treatment of indolent lymphomas. The presentation also outlines progress on a next-generation, PSMA-targeting ADC candidate that is advancing towards investigational new drug (IND) enabling activities. Internal market research is referenced to show ZYNLONTA's current position within U.S. treatment options for r/r DLBCL and potential for market share growth through combination therapies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADCT","symbol_name":"ADC Therapeutics SA","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL77284r:1","article_id":"2575058844","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575058844","pubTimestamp":1760356428,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ADC Therapeutics SA has released a new corporate presentation highlighting its commercial-stage activities in the field of antibody-drug conjugates . The company is focused on expanding its FDA-approved therapy ZYNLONTA for relapsed or refractory diffuse large B-cell lymphoma , with ongoing research into its use in earlier lines of therapy and additional indications, including combination regimens and treatment of indolent lymphomas. The presentation also outlines progress on a next-generation, PSMA-targeting ADC candidate that is advancing towards investigational new drug  enabling activities. Internal market research is referenced to show ZYNLONTA's current position within U.S. treatment options for r/r DLBCL and potential for market share growth through combination therapies. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADCT":"ADC Therapeutics SA","BK4139":"生物科技","BK4505":"高瓴资本持仓"},"translate_title":"ADC Therapeutics SA发布公司演示文稿重点介绍ZYNLONTA®ADC流水线的扩展和进步","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADCT":0.9},"content_text":"ADC Therapeutics SA Publishes Corporate Presentation Highlighting ZYNLONTA® Expansion and Advancements in ADC Pipeline\n    \n\n        ADC Therapeutics SA has released a new corporate presentation highlighting its commercial-stage activities in the field of antibody-drug conjugates (ADCs). The company is focused on expanding its FDA-approved therapy ZYNLONTA® for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), with ongoing research into its use in earlier lines of therapy and additional indications, including combination regimens and treatment of indolent lymphomas. The presentation also outlines progress on a next-generation, PSMA-targeting ADC candidate that is advancing towards investigational new drug (IND) enabling activities. Internal market research is referenced to show ZYNLONTA's current position within U.S. treatment options for r/r DLBCL and potential for market share growth through combination therapies. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}